PCN112 Lessons Learned From HTA Cost Effectiveness Evaluations of New Castration-Resistant Prostate Cancer Medications
Jun 1, 2012, 00:00 AM
10.1016/j.jval.2012.03.1229
https://www.valueinhealthjournal.com/article/S1098-3015(12)01294-6/fulltext
Section Title :
Cancer
Section Order :
752
First Page :
A228
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01294-6&doi=10.1016/j.jval.2012.03.1229